IL-10 potentiates differentiation of human induced regulatory T cells via STAT3 and Foxo1

Journal of Immunology

Volumn 195, Issue 8, 2015, Pages 3665-3674

  Hsu, Peter ^a,b   Santner Nanan, Brigitte ^a   Hu, Mingjing ^a   Skarratt, Kristen ^a   Lee, Cheng Hiang ^b   Stormon, Michael ^b   Wong, Melanie ^b   Fuller, Stephen J ^a   Nanan, Ralph ^a  

^a UNIVERSITY OF SYDNEY   (Australia)

^b CHILDREN S HOSPITAL AT WESTMEAD   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; INTERLEUKIN 10; INTERLEUKIN 10 RECEPTOR; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; STAT3 PROTEIN; TRANSCRIPTION FACTOR FKHR; TRANSFORMING GROWTH FACTOR BETA; FORKHEAD TRANSCRIPTION FACTOR; FOXO1 PROTEIN, HUMAN; IL10 PROTEIN, HUMAN; STAT3 PROTEIN, HUMAN;

ANTIGEN EXPRESSION; ARTICLE; CONTROLLED STUDY; ENZYME PHOSPHORYLATION; HUMAN; HUMAN CELL; INNATE IMMUNITY; LYMPHOCYTE DIFFERENTIATION; PRIORITY JOURNAL; PROTEIN DETERMINATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; REGULATORY T LYMPHOCYTE; SIGNAL TRANSDUCTION; CELL DIFFERENTIATION; DEFICIENCY; FEMALE; GENETICS; IMMUNOLOGY; MALE; MUTATION; PATHOLOGY;

CELL DIFFERENTIATION; FEMALE; FORKHEAD TRANSCRIPTION FACTORS; HUMANS; INTERLEUKIN-10; MALE; MUTATION; PROTO-ONCOGENE PROTEINS C-AKT; RECEPTORS, INTERLEUKIN-10; STAT3 TRANSCRIPTION FACTOR; T-LYMPHOCYTES, REGULATORY; TRANSFORMING GROWTH FACTOR BETA;

EID: 84943553806     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.1402898     Document Type: Article

References (52)

1. Mosser, D. M., and X. Zhang. 2008. Interleukin-10: new perspectives on an old cytokine. Immunol. Rev. 226:205-218.
2. Glocker, E.-O., D. Kotlarz, K. Boztug, E. M. Gertz, A. A. Schäffer, F. Noyan, M. Perro, J. Diestelhorst, A. Allroth, D. Murugan, et al. 2009. Inflammatory bowel disease and mutations affecting the interleukin-10 receptor. N. Engl. J. Med. 361:2033-2045.
3. Kotlarz, D., R. Beier, D. Murugan, J. Diestelhorst, O. Jensen, K. Boztug, D. Pfeifer, H. Kreipe, E.-D. Pfister, U. Baumann, et al. 2012. Loss of interleukin-10 signaling and infantile inflammatory bowel disease: implications for diagnosis and therapy. Gastroenterology 143:347-355.
4. Rubtsov, Y. P., J. P. Rasmussen, E. Y. Chi, J. Fontenot, L. Castelli, X. Ye, P. Treuting, L. Siewe, A. Roers, W. R. Henderson, Jr., et al. 2008. Regulatory T cell-derived interleukin-10 limits inflammation at environmental interfaces. Immunity 28:546-558.
5. Miyara, M., and S. Sakaguchi. 2007. Natural regulatory T cells: mechanisms of suppression. Trends Mol. Med. 13:108-116.
6. Chaudhry, A., R. M. Samstein, P. Treuting, Y. Liang, M. C. Pils, J.-M. Heinrich, R. S. Jack, F. T. Wunderlich, J. C. Brüning, W. Müller, and A. Y. Rudensky. 2011. Interleukin-10 signaling in regulatory T cells is required for suppression of Th17 cell-mediated inflammation. Immunity 34:566-578.
7. Murai, M., O. Turovskaya, G. Kim, R. Madan, C. L. Karp, H. Cheroutre, and M. Kronenberg. 2009. Interleukin 10 acts on regulatory T cells to maintain expression of the transcription factor Foxp3 and suppressive function in mice with colitis. Nat. Immunol. 10:1178-1184.
8. Zhou, L., I. I. Ivanov, R. Spolski, R. Min, K. Shenderov, T. Egawa, D. E. Levy, W. J. Leonard, and D. R. Littman. 2007. IL-6 programs T (H)-17 cell differentiation by promoting sequential engagement of the IL-21 and IL-23 pathways. Nat. Immunol. 8:967-974.
9. Fujimoto, M., M. Nakano, F. Terabe, H. Kawahata, T. Ohkawara, Y. Han, B. Ripley, S. Serada, T. Nishikawa, A. Kimura, et al. 2011. The influence of excessive IL-6 production in vivo on the development and function of Foxp3+ regulatory T cells. J. Immunol. 186:32-40.
10. Doganci, A., T. Eigenbrod, N. Krug, G. T. De Sanctis, M. Hausding, V. J. Erpenbeck, B. Haddad, H. A. Lehr, E. Schmitt, T. Bopp, et al. 2005. The IL-6R alpha chain controls lung CD4+CD25+ Treg development and function during allergic airway inflammation in vivo. J. Clin. Invest. 115:313-325.
11. Li, M. O., and R. A. Flavell. 2008. Contextual regulation of inflammation: a duet by transforming growth factor-beta and interleukin-10. Immunity 28:468-476.
12. Yamagiwa, S., J. D. Gray, S. Hashimoto, and D. A. Horwitz. 2001. A role for TGF-beta in the generation and expansion of CD4+CD25+ regulatory T cells from human peripheral blood. J. Immunol. 166:7282-7289.
13. Tran, D. Q. 2012. TGF-β: the sword, the wand, and the shield of FOXP3 (+) regulatory T cells. J. Mol. Cell Biol. 4:29-37.
14. Di Paolo, R. J., C. Brinster, T. S. Davidson, J. Andersson, D. Glass, and E. M. Shevach. 2007. Autoantigen-specific TGFbeta-induced Foxp3+ regulatory T cells prevent autoimmunity by inhibiting dendritic cells from activating autoreactive T cells. J. Immunol. 179:4685-4693.
15. Tran, D. Q., H. Ramsey, and E. M. Shevach. 2007. Induction of FOXP3 expression in naive human CD4+FOXP3 T cells by T-cell receptor stimulation is transforming growth factor-beta dependent but does not confer a regulatory phenotype. Blood 110:2983-2990.
16. Lu, L., J. Ma, Z. Li, Q. Lan, M. Chen, Y. Liu, Z. Xia, J. Wang, Y. Han, W. Shi, et al. 2011. All-trans retinoic acid promotes TGF-β-induced Tregs via histone modification but not DNA demethylation on Foxp3 gene locus. PLoS One 6:e24590.
17. Jeffery, L. E., F. Burke, M. Mura, Y. Zheng, O. S. Qureshi, M. Hewison, L. S. K. Walker, D. A. Lammas, K. Raza, and D. M. Sansom. 2009. 1, 25-Dihydroxyvitamin D3 and IL-2 combine to inhibit T cell production of inflammatory cytokines and promote development of regulatory T cells expressing CTLA-4 and FoxP3. J. Immunol. 183:5458-5467.
18. Battaglia, M., A. Stabilini, B. Migliavacca, J. Horejs-Hoeck, T. Kaupper, and M.-G. Roncarolo. 2006. Rapamycin promotes expansion of functional CD4+CD25+FOXP3+ regulatory T cells of both healthy subjects and type 1 diabetic patients. J. Immunol. 177:8338-8347.
19. Shouval, D. S., A. Biswas, J. A. Goettel, K. McCann, E. Conaway, N. S. Redhu, I. D. Mascanfroni, Z. Al Adham, S. Lavoie, M. Ibourk, et al. 2014. Interleukin-10 receptor signaling in innate immune cells regulates mucosal immune tolerance and anti-inflammatory macrophage function. Immunity 40:706-719.
20. Santner-Nanan, B., M. J. Peek, R. Khanam, L. Richarts, E. Zhu, B. Fazekas de St Groth, and R. Nanan. 2009. Systemic increase in the ratio between Foxp3+ and IL-17-producing CD4+ T cells in healthy pregnancy but not in preeclampsia. J. Immunol. 183:7023-7030.
21. Baron, U., S. Floess, G. Wieczorek, K. Baumann, A. Grützkau, J. Dong, A. Thiel, T. J. Boeld, P. Hoffmann, M. Edinger, et al. 2007. DNA demethylation in the human FOXP3 locus discriminates regulatory T cells from activated FOXP3 (+) conventional T cells. Eur. J. Immunol. 37:2378-2389.
22. Boonstra, A., R. Rajsbaum, M. Holman, R. Marques, C. Asselin-Paturel, J. P. Pereira, E. E. Bates, S. Akira, P. Vieira, Y.-J. Liu, et al. 2006. Macrophages and myeloid dendritic cells, but not plasmacytoid dendritic cells, produce IL-10 in response to MyD88- and TRIF-dependent TLR signals, and TLR-independent signals. J. Immunol. 177:7551-7558.
23. Lee, C. H., P. Hsu, B. Nanan, R. Nanan, M. Wong, K. J. Gaskin, R. W. Leong, R. Murchie, A. M. Muise, and M. O. Stormon. 2014. Novel de novo mutations of the interleukin-10 receptor gene lead to infantile onset inflammatory bowel disease. J. Crohn's Colitis 8:1551-1556.
24. Donnelly, R. P., H. Dickensheets, and D. S. Finbloom. 1999. The interleukin-10 signal transduction pathway and regulation of gene expression in mononuclear phagocytes. J. Interferon Cytokine Res. 19:563-573.
25. Schust, J., B. Sperl, A. Hollis, T. U. Mayer, and T. Berg. 2006. Stattic: a smallmolecule inhibitor of STAT3 activation and dimerization. Chem. Biol. 13:1235-1242.
26. Goodman, W. A., A. B. Young, T. S. McCormick, K. D. Cooper, and A. D. Levine. 2011. Stat3 phosphorylation mediates resistance of primary human T cells to regulatory T cell suppression. J. Immunol. 186:3336-3345.
27. Ives, M. L., C. S. Ma, U. Palendira, A. Chan, J. Bustamante, S. Boisson-Dupuis, P. D. Arkwright, D. Engelhard, D. Averbuch, K. Magdorf, et al. 2013. Signal transducer and activator of transcription 3 (STAT3) mutations underlying autosomal dominant hyper-IgE syndrome impair human CD8 (+) T-cell memory formation and function. J. Allergy Clin. Immunol. 132:400-411.e9.
28. Renner, E. D., S. Rylaarsdam, S. Anover-Sombke, A. L. Rack, J. Reichenbach, J. C. Carey, Q. Zhu, A. F. Jansson, J. Barboza, L. F. Schimke, et al. 2008. Novel signal transducer and activator of transcription 3 (STAT3) mutations, reduced T (H) 17 cell numbers, and variably defective STAT3 phosphorylation in hyper-IgE syndrome. J. Allergy Clin. Immunol. 122:181-187.
29. Taylor, A., M. Akdis, A. Joss, T. Akkoç, R. Wenig, M. Colonna, I. Daigle, E. Flory, K. Blaser, and C. A. Akdis. 2007. IL-10 inhibits CD28 and ICOS costimulations of T cells via src homology 2 domain-containing protein tyrosine phosphatase 1. J. Allergy Clin. Immunol. 120:76-83.
30. Kops, G. J., R. H. Medema, J. Glassford, M. A. Essers, P. F. Dijkers, P. J. Coffer, E. W. Lam, and B. M. Burgering. 2002. Control of cell cycle exit and entry by protein kinase B-regulated forkhead transcription factors. Mol. Cell. Biol. 22:2025-2036.
31. Ouyang, W., W. Liao, C. T. Luo, N. Yin, M. Huse, M. V. Kim, M. Peng, P. Chan, Q. Ma, Y. Mo, et al. 2012. Novel Foxo1-dependent transcriptional programs control T (reg) cell function. Nature 491:554-559.
32. Medema, R. H., G. J. Kops, J. L. Bos, and B. M. Burgering. 2000. AFX-like Forkhead transcription factors mediate cell-cycle regulation by Ras and PKB through p27kip1. Nature 404:782-787.
33. Nagashima, T., N. Shigematsu, R. Maruki, Y. Urano, H. Tanaka, A. Shimaya, T. Shimokawa, and M. Shibasaki. 2010. Discovery of novel forkhead box O1 inhibitors for treating type 2 diabetes: improvement of fasting glycemia in diabetic db/db mice. Mol. Pharmacol. 78:961-970.
34. Kerdiles, Y. M., D. R. Beisner, R. Tinoco, A. S. Dejean, D. H. Castrillon, R. A. DePinho, and S. M. Hedrick. 2009. Foxo1 links homing and survival of naive T cells by regulating L-selectin, CCR7 and interleukin 7 receptor. Nat. Immunol. 10:176-184.
35. de Waal Malefyt, R., J. Abrams, B. Bennett, C. G. Figdor, and J. E. de Vries. 1991. Interleukin 10 (IL-10) inhibits cytokine synthesis by human monocytes: an autoregulatory role of IL-10 produced by monocytes. J. Exp. Med. 174:1209-1220.
36. de Waal Malefyt, R., H. Yssel, and J. E. de Vries. 1993. Direct effects of IL-10 on subsets of human CD4+ T cell clones and resting T cells. Specific inhibition of IL-2 production and proliferation. J. Immunol. 150:4754-4765.
37. Jarry, A., C. Bossard, C. Bou-Hanna, D. Masson, E. Espaze, M. G. Denis, and C. L. Laboisse. 2008. Mucosal IL-10 and TGF-beta play crucial roles in preventing LPS-driven, IFN-gamma-mediated epithelial damage in human colon explants. J. Clin. Invest. 118:1132-1142.
38. Fuss, I. J., M. Boirivant, B. Lacy, and W. Strober. 2002. The interrelated roles of TGF-beta and IL-10 in the regulation of experimental colitis. J. Immunol. 168:900-908.
39. Cottrez, F., and H. Groux. 2001. Regulation of TGF-beta response during T cell activation is modulated by IL-10. J. Immunol. 167:773-778.
40. Akdis, C. A., A. Joss, M. Akdis, A. Faith, and K. Blaser. 2000. A molecular basis for T cell suppression by IL-10: CD28-associated IL-10 receptor inhibits CD28 tyrosine phosphorylation and phosphatidylinositol 3-kinase binding. [Published erratum appears in FASEB J. 2000 Oct. 14(13):2128.] FASEB J. 14:1666-1668.
41. Ouyang, W., O. Beckett, Q. Ma, J. H. Paik, R. A. DePinho, and M. O. Li. 2010. Foxo proteins cooperatively control the differentiation of Foxp3+ regulatory T cells. Nat. Immunol. 11:618-627.
42. Kerdiles, Y. M., E. L. Stone, D. R. Beisner, M. A. McGargill, I. L. Ch'en, C. Stockmann, C. D. Katayama, and S. M. Hedrick. 2010. Foxo transcription factors control regulatory T cell development and function. Immunity 33:890-904.
43. Saito, M., M. Nagasawa, H. Takada, T. Hara, S. Tsuchiya, K. Agematsu, M. Yamada, N. Kawamura, T. Ariga, I. Tsuge, et al. 2011. Defective IL-10 signaling in hyper-IgE syndrome results in impaired generation of tolerogenic dendritic cells and induced regulatory T cells. J. Exp. Med. 208:235-249.
44. Pallandre, J.-R., E. Brillard, G. Créhange, A. Radlovic, J.-P. Remy-Martin, P. Saas, P.-S. Rohrlich, X. Pivot, X. Ling, P. Tiberghien, and C. Borg. 2007. Role of STAT3 in CD4+CD25+FOXP3+ regulatory lymphocyte generation: implications in graft-versus-host disease and antitumor immunity. J. Immunol. 179:7593-7604.
45. Laurence, A., S. Amarnath, J. Mariotti, Y. C. Kim, J. Foley, M. Eckhaus, J. J. O'Shea, and D. H. Fowler. 2012. STAT3 transcription factor promotes instability of nTreg cells and limits generation of iTreg cells during acute murine graft-versus-host disease. Immunity 37:209-222.
46. Yasukawa, H., M. Ohishi, H. Mori, M. Murakami, T. Chinen, D. Aki, T. Hanada, K. Takeda, S. Akira, M. Hoshijima, et al. 2003. IL-6 induces an antiinflammatory response in the absence of SOCS3 in macrophages. Nat. Immunol. 4:551-556.
47. Braun, D. A., M. Fribourg, and S. C. Sealfon. 2013. Cytokine response is determined by duration of receptor and signal transducers and activators of transcription 3 (STAT3) activation. J. Biol. Chem. 288:2986-2993.
48. Oh, H.-M., C.-R. Yu, I. Dambuza, B. Marrero, and C. E. Egwuagu. 2012. STAT3 protein interacts with Class O Forkhead transcription factors in the cytoplasm and regulates nuclear/cytoplasmic localization of FoxO1 and FoxO3a proteins in CD4 (+) T cells. J. Biol. Chem. 287:30436-30443.
49. Merkenschlager, M., and H. von Boehmer. 2010. PI3 kinase signalling blocks Foxp3 expression by sequestering Foxo factors. J. Exp. Med. 207:1347-1350.
50. Hippen, K. L., S. C. Merkel, D. K. Schirm, C. Nelson, N. C. Tennis, J. L. Riley, C. H. June, J. S. Miller, J. E. Wagner, and B. R. Blazar. 2011. Generation and large-scale expansion of human inducible regulatory T cells that suppress graftversushost disease. Am. J. Transplant. 11:1148-1157.
51. Yadav, M., S. Stephan, and J. A. Bluestone. 2013. Peripherally induced tregs - role in immune homeostasis and autoimmunity. Front. Immunol. 4:232.
52. Haribhai, D., J. B. Williams, S. Jia, D. Nickerson, E. G. Schmitt, B. Edwards, J. Ziegelbauer, M. Yassai, S.-H. Li, L. M. Relland, et al. 2011. A requisite role for induced regulatory T cells in tolerance based on expanding antigen receptor diversity. Immunity 35:109-122.